Home > Late Breaking Trials and First Report Investigations
Late Breaking Trials and First Report Investigations

    NOYA I: A Prospective Randomized Trial of NOYA Sirolimus-Eluting Stent with Biodegradable Coating Compared to FIREBIRD 2 Sirolimus-Eluting Stent with Durable Coating in Patients with Coronary Artery Disease - Run-Lin Gao, MD

    CREST-MI: Comparison of Safety and Efficacy between CYPHER Stent and ENDEAVOR Stent in Patients with Acute ST-Segment Elevation Myocardial Infarction - Lefeng Wang, MD

    MICD-STEMI PCI: Multicenter Investigation of Compound Danshen Dripping Pills on Short-Term Clinical Events in Patient with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI - Guangping Li, MD

    JETSTENT: Role of Thrombectomy Devices during PCI in ST-Segment Elevation Myocardial Infarction - Alfredo E. Rodriguez, MD, PhD

    DK-CRUSH IV: Hemodynamic Change of FFR after DK Crush vs. Provisional T Stenting for Coronary Bifurcation Lesions - Shaoliang Chen, MD

    FOCUS 6-Month Update: FIREBIRD 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry - Junbo Ge, MD

    CREATE 4-Year Update: Multicenter Registry of EXCEL Biodegradable Polymer Drug-Eluting Stents - Yaling Han, MD

    FIREMAN 3-Year Update: Efficacy and Safety of FIREBIRD Sirolimus-Eluting Stent in Complex Coronary Lesions - Yan Li, MD

    TEDA-Thrombosis Registry: Triple Antiplatelet (Aspirin, Clopidogrel, and Low-Dose Tirofiban) Therapy Reduces 30-Day Risk of Stent Thrombosis after Drug-Eluting Stent Implantation - Xiangqian Qi, MD

    Clinical Outcomes with Sirolimus-Eluting Stents and Zotarolimus-Eluting Stents in Routine Clinical Practice - Fang Chen, MD

    SAME-DES Registry: Angiographic and IVUS Follow-Up after Simultaneously Implanted Different Drug-Eluting Stents in Same Individuals - Dingcheng Xiang, MD

    COSAFE: Comparison of Safety and Efficacy between Fondaparinux and Nadroparin in Non-ST Elevation Acute Coronary Syndromes - Hongbing Yan, MD

    FIM-TARGET: A First-in-Man Trial of FIREHAWK Biodegradable Polymer Target Release Rapamycin-Eluting Stent: 4- and 12-Month Angiographic, 4-Month OCT, and 12-Month Clinical Results - Jie Qian, MD

    CTO-1: Collagenase Total Occlusion-1 Trial - Bradley H. Strauss, MD, PhD

    SPIDER PFO Closure System First-in-Man Study - Horst Sievert, MD

    Transcatheter Closure of Ventricular Septal Defect in Combination with Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Complicating Ventricular Septal Defect - Yaling Han, MD

    BHMS: Beijing Heart and Metabolism Survey - Yujie Zhou, MD